Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction
Pierre-Louis B et al. – Risk of developing major adverse cardiac events was 1.8 times greater for pts with bare-metal (BMS) vs drug-eluting stents (DES) after controlling confounding effects of previous coronary artery bypass surgery and stent width. Methods- Percutaneous coronary intervention with stenting for 376 pts after thrombolytic therapy with tenecteplase for ST-segment elevation acute myocardial infarction
Results- Of 376 pts, BMS for 102 (27%); DES for 274 (73%) with sirolimus- or paclitaxel-eluting stents
- At 43 mo of follow-up, major adverse cardiac events in 25 (25%) of 102 BMS pts vs 40 (15%) of 274 DES pts
- On Cox regression analysis, significant independent prognostic factors for major adverse cardiac events: previous coronary artery bypass surgery, width of stent, and bare-metal stent
[more...]
|
|
|
